Japan PPI inflation slips to 11-mth low in July
On Wednesday, BMO Capital analysts increased the price target for BridgeBio Pharma stock (NASDAQ: NASDAQ:BBIO) to $42 from a previous target of $37. Despite this adjustment, the analysts maintained a Market Perform rating for the company. According to InvestingPro data, the stock is currently trading above its Fair Value, with the share price hovering near its 52-week high of $39.54. The decision reflects updated expectations for the company’s sales performance in the second quarter of 2025.
The analysts anticipate that BridgeBio Pharma’s US sales for Attruby in the second quarter will range between $77 million and $89 million. This projection indicates a quarter-over-quarter growth of approximately 110% to 145%, and revenues that are 20% to 40% above consensus estimates. The company maintains strong liquidity with a current ratio of 4.57, though it remains unprofitable with an EBITDA of -$662.65 million in the last twelve months.
The analysts expect the second-quarter sales announcement to potentially drive a 5% to 15% increase in BridgeBio Pharma’s stock, with an estimated 80% probability of this outcome. This forecast aligns with the stock’s recent momentum, having gained 16.31% in the past week and 38.45% over the last six months. Get deeper insights into BBIO’s valuation and growth potential with InvestingPro, which offers exclusive analysis and 8 additional ProTips for this stock.
The analysts noted that they are updating their model estimates to align with these expectations for Attruby sales. They also highlighted the rapid growth in the ATTR-CM market, which appears to be expanding faster than previously anticipated.
BridgeBio Pharma continues to be monitored closely by BMO Capital, as the ATTR-CM market dynamics evolve. The analysts’ revised price target reflects their current outlook on the company’s potential performance in the coming months.
In other recent news, BridgeBio Pharma has reported strong financial results for the first quarter of 2025, with total revenues reaching $116.6 million, significantly surpassing the forecasted $54.46 million. The company’s product, Attruby, generated $36.7 million in net revenue, driven by high physician demand and successful commercial performance. BridgeBio’s strategic focus on patient access and support has further enhanced its competitive position in the ATTR cardiomyopathy market. In addition to financial achievements, BridgeBio announced the dosing of the first participant in the ACT-EARLY clinical trial, aimed at preventing transthyretin amyloid disease. The trial seeks to enroll approximately 600 asymptomatic carriers of the TTR variant, with endpoints including safety and effects on cardiac imaging parameters. Furthermore, Scotiabank (TSX:BNS) has raised BridgeBio’s stock target to $55, citing strong sales of Attruby. The company also shared promising results from its ATTRibute-CM Phase 3 trial, where its drug acoramidis demonstrated significant reductions in all-cause mortality and cardiovascular-related hospitalizations. These developments reflect BridgeBio’s ongoing commitment to addressing unmet needs in genetic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.